Table 2.
HCV patient characteristics and outcome of evaluation
| N = 4 (100%) | |
|---|---|
| Sex | |
| Male | 2 (50%) |
| Female | 2 (50%) |
| Age (years) (mean ± SD) | 59 ± 21 |
| Migrational background | |
| Dutch / WE | 3 (75%) |
| EE/EA | 1 (25%) |
| ALT (U/l) (mean + SD) | 35 ± 18 |
| Normal (0-34 U/l) | 3 (75%) |
| > 1xULN | 1 (25%) |
| Viral load (IU/mL) (median) | 137,605 |
| Fibrosis stage | |
| F0-F1 | 3 (75%) |
| F2-F3 | 1 (25%) |
| Management advice | |
| No therapy | 1 (25%) |
| Antiviral therapy | 3 (75%) |
WE Western Europe, EE Eastern Europe, EA Euro Asia, ALT Alanine-aminotransferase, ULN Upper limit of normal